Daily Stock Analysis, JAZZ, Jazz Pharmaceuticals PLC, priceseries

Jazz Pharmaceuticals PLC. Daily Stock Analysis
Stock Information
Open
133.32
Close
131.39
High
133.32
Low
129.22
Previous Close
133.35
Daily Price Gain
-1.96
YTD High
144.94
YTD High Date
Apr 8, 2019
YTD Low
119.54
YTD Low Date
Feb 12, 2019
YTD Price Change
6.26
YTD Gain
5.00%
52 Week High
176.73
52 Week High Date
Aug 20, 2018
52 Week Low
113.52
52 Week Low Date
Dec 24, 2018
52 Week Price Change
-41.73
52 Week Gain
-24.10%
Recent priceSeries Trade Signals

These are sample algorithmic trades based on actual market data.

Trade Type
Entry Date
Entry Price
Exit Date
Exit Price
Trade Hold Time
Gain
Trade Record
LONG
Dec 30. 2016
109.03
Jan 24. 2017
120.38
15 Trading Days
10.41%
Link
LONG
Jan 31. 2017
121.92
Feb 28. 2017
132.09
19 Trading Days
8.34%
Link
LONG
May 30. 2018
168.48
Jun 22. 2018
178.50
17 Trading Days
5.95%
Link
Company Information
Stock Symbol
JAZZ
Exchange
NasdaqGS
Company URL
http://www.jazzpharma.com
Company Phone
353-1-634-7800
CEO
Bruce C. Cozadd
Headquarters
-
Business Address
FIFTH FLOOR, WATERLOO EXCHANGE, WATERLOO ROAD, DUBLIN, IRELAND 4
Sector
Equity
Industry Category
Drugs
Industry Group
Biotechnology
CIK
0001232524
About

Jazz Pharmaceuticals Plc operates as a specialty biopharmaceutical company, which focuses on the identification, development and commercialization of pharmaceutical products. It has a diverse portfolio of products in the areas of narcolepsy, oncology, pain and psychiatry. Its product portfolio includes: XYREM, ERWINAZETM, PRIALT, intrathecal infusion, FAZACLO and LUVOX CR. The company was founded by Bruce C. Cozadd on January 18, 2012 and is headquartered in Dublin, Ireland.

Description

Jazz Pharmaceuticals Public Limited Company, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for various medical needs in the United States, Europe, and internationally. The company has a portfolio of products and product candidates with a focus in the areas of sleep and hematology/oncology. It markets Xyrem, an oral solution for the treatment of cataplexy and excessive daytime sleepiness (EDS) in patients with narcolepsy; Erwinaze to treat acute lymphoblastic leukemia (ALL); Defitelio for the treatment and prevention of severe hepatic veno-occlusive disease, a potentially life-threatening complication of hematopoietic stem cell transplantation; and Prialt, an intrathecally administered infusion of ziconotide for the management of severe chronic pain. The company also develops JZP-110, which is in phase III clinical trial for the treatment of excessive sleepiness (ES) in patients with narcolepsy and obstructive sleep apnea, as well as phase II clinical trial for ES associated with Parkinson's disease; Vyxeos (CPX-351) for high-risk acute myeloid leukemia; and JZP-507 and JZP-258 to treat EDS and cataplexy in narcolepsy, as well as evaluates deuterated oxybate for narcolepsy. In addition, it sells psychiatry and other products. The company is headquartered in Dublin, Ireland.